Don W. Shaffer

814 total citations
11 papers, 678 citations indexed

About

Don W. Shaffer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Don W. Shaffer has authored 11 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Don W. Shaffer's work include Cancer therapeutics and mechanisms (2 papers), Lymphoma Diagnosis and Treatment (1 paper) and Neutropenia and Cancer Infections (1 paper). Don W. Shaffer is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Lymphoma Diagnosis and Treatment (1 paper) and Neutropenia and Cancer Infections (1 paper). Don W. Shaffer collaborates with scholars based in United States, Germany and Italy. Don W. Shaffer's co-authors include John D. Hainsworth, F. Anthony Greco, Sharlene Litchy, Manuel Grimaldi, Howard A. Burris, Gladys Rodriguez, Geoffrey R. Weiss, John G. Kuhn, Suzanne M. Fields and John R. Eckardt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Don W. Shaffer

11 papers receiving 649 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Don W. Shaffer United States 8 407 273 151 151 138 11 678
James E. Bradof United States 13 547 1.3× 322 1.2× 234 1.5× 272 1.8× 110 0.8× 19 874
H.‐G. Mergenthaler Germany 12 543 1.3× 206 0.8× 173 1.1× 212 1.4× 111 0.8× 33 903
Geoffrey Chong Australia 15 393 1.0× 307 1.1× 179 1.2× 117 0.8× 151 1.1× 59 769
Shozo Mori Japan 11 288 0.7× 241 0.9× 84 0.6× 201 1.3× 138 1.0× 63 688
A. M. Gianni Italy 15 294 0.7× 201 0.7× 83 0.5× 101 0.7× 109 0.8× 26 619
Harish K. Gagneja United States 7 436 1.1× 512 1.9× 223 1.5× 306 2.0× 112 0.8× 14 855
Myung Hee Chang South Korea 17 385 0.9× 205 0.8× 73 0.5× 246 1.6× 118 0.9× 50 718
Elber S. Camacho United States 11 474 1.2× 210 0.8× 202 1.3× 110 0.7× 444 3.2× 24 929
D Hossfeld Germany 11 362 0.9× 191 0.7× 67 0.4× 181 1.2× 104 0.8× 27 614
Mei Dong China 14 379 0.9× 442 1.6× 68 0.5× 79 0.5× 241 1.7× 49 775

Countries citing papers authored by Don W. Shaffer

Since Specialization
Citations

This map shows the geographic impact of Don W. Shaffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don W. Shaffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don W. Shaffer more than expected).

Fields of papers citing papers by Don W. Shaffer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don W. Shaffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don W. Shaffer. The network helps show where Don W. Shaffer may publish in the future.

Co-authorship network of co-authors of Don W. Shaffer

This figure shows the co-authorship network connecting the top 25 collaborators of Don W. Shaffer. A scholar is included among the top collaborators of Don W. Shaffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don W. Shaffer. Don W. Shaffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Petrylak, Daniel P., Manish Kohli, Andrew Eisen, et al.. (2015). 2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. European Journal of Cancer. 51. S476–S476. 3 indexed citations
2.
Tait, Robert C., Don W. Shaffer, F. Baudo, et al.. (2008). Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thrombosis and Haemostasis. 99(3). 616–622. 27 indexed citations
3.
4.
Hainsworth, John D., James R. Gray, Sharlene Litchy, et al.. (2004). A Phase II Trial of Preoperative Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin for Patients with Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 6(1). 33–42. 9 indexed citations
5.
6.
Greco, F. Anthony, Gladys Rodriguez, Don W. Shaffer, et al.. (2004). Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial. The Oncologist. 9(6). 644–652. 41 indexed citations
7.
Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (2003). Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 21(2). 193–199. 19 indexed citations
8.
Meluch, Anthony A., F. Anthony Greco, James R. Gray, et al.. (2003). Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal. 9(4). 251–260. 92 indexed citations
9.
Burris, Howard A., John G. Kuhn, Lee Smith, et al.. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology. 11(5). 950–958. 120 indexed citations
10.
Shaffer, Don W., et al.. (1993). Fine‐needle aspiration biopsy of multiple myeloma in a patient with renal‐cell carcinoma: A case report. Diagnostic Cytopathology. 9(5). 551–554. 7 indexed citations
11.
Burris, Howard A., Daniel D. Von Hoff, Gladys Rodriguez, et al.. (1992). A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs. 3(4). 337–346. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James E. Bradof Breakdown of academic impact, for papers by H.‐G. Mergenthaler Breakdown of academic impact, for papers by Geoffrey Chong Breakdown of academic impact, for papers by Shozo Mori Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Harish K. Gagneja Breakdown of academic impact, for papers by Myung Hee Chang Breakdown of academic impact, for papers by Elber S. Camacho Breakdown of academic impact, for papers by D Hossfeld Breakdown of academic impact, for papers by Mei Dong
Rankless by CCL
2026